Valeant Pharmaceuticals International Inc has brought in investment banks to review its options amid interest from buyout firms and other companies in a number of its businesses, according to people familiar with the matter.
While Valeant has not decided to sell any major business thus far, the move represents the clearest indication yet that the Canadian drug maker needs to divest assets to bolster its finances, the people said this week.
Valeant has turned to investment banks that include Goldman Sachs Group Inc (GS.S) and Centerview Partners Holdings LLC as it reviews strategic options and seeks advice on dealing with its creditors, the people added.
The sources asked not to be identified because the deliberations are confidential. Valeant did not respond to requests for comment. Goldman Sachs and Centerview declined to comment.
Both Valeant Chief Executive Officer Michael Pearson and board member William Ackman, who is also the CEO of activist hedge fund Pershing Square, have said that the company was considering selling “noncore assets” to help trim its $30 billion debt pile.
Since announcing its openness to asset sales, Valeant has received a flurry of inquiries from interested buyers, according to the sources.
One coveted asset is Xifaxin, the largest product in Valeant’s gastrointestinal division, which it acquired last year as part of its $11 billion acquisition of Salix Pharmaceuticals, the sources said.
Other assets that have attracted interest from potential bidders include its aesthetics products, Obagi and Solta, and its skin care product, CeraVe, some of the sources added.
Valeant has been under pressure to reduce its debt burden after its stock plunged more than 80 percent since August due to increased political criticism of high drug prices and controversy around its relationship with a specialty pharmacy.
Ratings agencies S&P and Moody’s have downgraded the company’s credit rating, and lenders have demanded higher coupon payments after the company violated certain debt agreements pertaining to the timing of the filing of its 10-K.
Valeant has undergone changes in recent months such as adding several new board seats, including a spot for Ackman, and asking Pearson to step down. A search for a new CEO is under way while Pearson remains in his post.
By Olivia Oran and Carl O’Donnell in New York
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.